STAT+: FDA advisory panel narrowly recommends approval for Sarepta’s gene therapy for Duchenne
A panel of independent advisers to the FDA narrowly voted 8 to 6 to recommend accelerated approval for Sarepta’s gene therapy for Duchenne muscular dystrophy.
For an archived version of a live blog about Friday’s FDA advisory panel hearing, click here.
A panel of independent advisers to the Food and Drug Administration narrowly voted 8-6 to recommend accelerated approval for Sarepta’s gene therapy for Duchenne muscular dystrophy, ruling that the potential benefit to patients outweighs a long list of concerns from the agency’s reviewers.
What's Your Reaction?
